CUSIP: 45719W106
Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
3,058,668
-
Share change
-
-291,663
-
Total reported value
-
$2,780,115
-
Price per share
-
$0.91
-
Number of holders
-
23
-
Value change
-
-$196,503
-
Number of buys
-
6
-
Number of sells
-
6
Quarterly Holders Quick Answers
What is CUSIP 45719W106?
CUSIP 45719W106 identifies IKT - INHIBIKASE THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2022
-
Previous quarter:
Q2 2022
Recent filing periods for CUSIP 45719W106:
Institutional Holders of INHIBIKASE THERAPEUTICS INC - COM (IKT) as of Q3 2022
As of 30 Sep 2022,
INHIBIKASE THERAPEUTICS INC - COM (IKT) was held by
23 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,058,668 shares.
The largest 10 holders included
ACT CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, FMR LLC, BLAIR WILLIAM & CO/IL, HAMILTON LANE ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, Redmond Asset Management, LLC, ZEKE CAPITAL ADVISORS, LLC, GEODE CAPITAL MANAGEMENT, LLC, and Koshinski Asset Management, Inc..
This page lists
23
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.